These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. Barbouche R, Decroly E, Kieny MP, Fenouillet E. Virology; 2000 Jul 20; 273(1):169-77. PubMed ID: 10891419 [Abstract] [Full Text] [Related]
6. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. Szabó J, Cervenák L, Tóth FD, Prohászka Z, Horváth L, Kerekes K, Beck Z, Bácsi A, Erdei A, Peerschke EI, Füst G, Ghebrehiwet B. Clin Immunol; 2001 May 20; 99(2):222-31. PubMed ID: 11318594 [Abstract] [Full Text] [Related]
7. Structural basis for the interaction between focal adhesion kinase and CD4. Garron ML, Arthos J, Guichou JF, McNally J, Cicala C, Arold ST. J Mol Biol; 2008 Feb 01; 375(5):1320-8. PubMed ID: 18078954 [Abstract] [Full Text] [Related]
8. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes. Jagodzinski PP, Wustner J, Kmieciak D, Wasik TJ, Fertala A, Sieron AL, Takahashi M, Tsuji T, Mimura T, Fung MS, Gorny MK, Kloczewiak M, Kaneko Y, Kozbor D. Virology; 1996 Dec 15; 226(2):217-27. PubMed ID: 8955041 [Abstract] [Full Text] [Related]
9. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection. Zanotto C, Calderazzo F, Dettin M, Di Bello C, Autiero M, Guardiola J, Chieco-Bianchi L, De Rossi A. Virology; 1995 Feb 01; 206(2):807-16. PubMed ID: 7856094 [Abstract] [Full Text] [Related]
15. Inhibition of human immunodeficiency virus infection by the lectin jacalin and by a derived peptide showing a sequence similarity with gp120. Favero J, Corbeau P, Nicolas M, Benkirane M, Travé G, Dixon JF, Aucouturier P, Rasheed S, Parker JW, Liautard JP. Eur J Immunol; 1993 Jan 10; 23(1):179-85. PubMed ID: 8419169 [Abstract] [Full Text] [Related]
17. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II). Otaka A, Tamamura H, Terakawa Y, Masuda M, Koide T, Murakami T, Nakashima H, Matsuzaki K, Miyajima K, Ibuka T. Biol Pharm Bull; 1994 Dec 10; 17(12):1669-72. PubMed ID: 7735216 [Abstract] [Full Text] [Related]
18. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. Virology; 2005 Sep 01; 339(2):213-25. PubMed ID: 15996703 [Abstract] [Full Text] [Related]